<DOC>
	<DOCNO>NCT00987363</DOCNO>
	<brief_summary>The aim study evaluate safety feasibility autologous bone marrow mononuclear cell autologous administer intra-arterially affected limb diabetic patient chronic critical ischemia lower limb ( CLI ) without possibility revascularization therapeutic alternative . The trial hypothesis propose consist mononuclear cell bone marrow provide progenitor cell regenerative capacity secrete also several angiogenic factor , implantation ischemic tissue element contribute angiogenesis tissue regeneration recovery circulation affect limb</brief_summary>
	<brief_title>Intraarterial Infusion Autologous Bone Marrow Diabetic Patients With Chronic Ischemia Lower Limbs ( CLI ) Revascularization</brief_title>
	<detailed_description>Phase II Clinical Trial , prospective , multicenter , open , randomize , parallel-group control three dose level . The study population consist total 60 diabetic patient chronic critical ischemia one leg ( CLI ) possibility revascularization . In experimental group include total 45 patient divide three dose level , 15 patient level ( increase dos mononuclear cell bone marrow evenly ) 15 patient control group ( cell therapy ) . Patients randomly assign either control group three experimental group dose mononuclear cell bone marrowo : - Group 1 ( 15 patient ) : cell therapy . - Group 2 ( 15 patient ) : 1x108 mononuclear cell bone marrow - Gropu 3 ( 15 patient ) : 5x108 mononuclear cell bone marrow - Group 4 ( 15 patient ) : 1x109 mononuclear cell bone marrow The cell therapy medicinal product shall administer case intraarterially . Patients evaluate clinical , radiological angiologist method . This randomize controlled trial safety feasibility cell therapy medicinal product shall measure compare response variable treatment compare baseline prior implementation . Secondarily result obtain compare dose group . Patients receive concomitant way drug treatment establish good practice , would certainly possible improvement occurs due drug treatment . The primary variable improvement vascularizaci√≥n treat limb determine clinical , angiologic angiographic parameter . It estimate inclusion period last twelve eighteen month twelve month follow-up . Therefore total study duration range twenty-four thirty month inclusion first patient end follow-up last patient include . Objectives study : - Main objective : To evaluate safety feasibility mononuclear cell autologous bone marrow administer intra-arterially affected limb diabetic patient chronic critical ischemia lower limb without possibility revascularization therapeutic alternative . Secondary objective :</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>1 . Type 1 2 diabetes mellitus 2 . Grade IIIII RutherfordBecker peripheral vascular disease affect least one limb 3 . Arterial obstruction ( ) locate infrapopliteal level 4 . No option endoarterial surgical revascularization 5 . Life expectancy 2 year 6 . Unlikelihood major amputation leg next 12 month 7 . Normal analytical parameter blood : leucocytes &gt; 3000/micoL , neutrophil &gt; 1500 microL , Hb &gt; 10mg/dl , platelet &gt; 100000 microL , AST ALT &lt; 2.5 standard value , creatinin &lt; 2.5 mg/dl 8 . Written inform consent 9 . Negative pregnancy test applicable 1 . History neoplasm hematological disease 2 . Uncontrolled high blood pressure ( &gt; 180/110 ) 3 . Severe cardiac insufficiency ( NYHA IV ) ejection fraction &lt; 30 % 4 . Malignant ventricular arrythmia 5 . Deep venous thrombosis last 3 month 6 . Active bacterial infection 7 . Treatment hyperbaric oxygen , vasoactive drug , CoxII inhibitors antiangiogenic agent 8 . Body mass index &gt; 40 9 . Alcoholism 10 . Proliferative retinopathy 11 . HIV , HBV HCV viral infection 12 . Stroke myocardial infarction last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>critical limb ischemia ( CLI )</keyword>
	<keyword>diabetic foot</keyword>
	<keyword>bone marrow derive mononuclear cell</keyword>
	<keyword>cell therapy</keyword>
</DOC>